Laryngopharyngeal Reflux: Prospective Cohort Study Evaluating Optimal Dose of Proton-Pump Inhibitor Therapy and Pretherapy Predictors of Response

Park, Woosuk; Hicks, Douglas M.; Khandwala, Farah; Richter, Joel E.; Abelson, Tom I.; Milstein, Claudio F.; Vaezi, Michael F.

doi:10.1097/01.mlg.0000163746.81766.45

Cited by 230 publications

(198 citation statements)

References 13 publications

Supporting

Mentioning

177

Contrasting

Unclassified

Order By: Relevance

“…Paradoxically, the success achieved in the Group C was lower than Groups A and B, though, significant improvement was seen with this intervention as well 11 .…”

Section: Resultsmentioning

confidence: 73%

See 1 more Smart Citation

Analyzing various non-surgical treatment modalities for laryngopharyngeal reflux

Owais

Rahil

Anees

et al. 2012

Bangladesh J of Otorhinolaryngology

View full text Add to dashboard Cite

show abstract

“…Paradoxically, the success achieved in the Group C was lower than Groups A and B, though, significant improvement was seen with this intervention as well 11 .…”

Section: Resultsmentioning

confidence: 73%

“…7 Twice daily dosage of PPIs has been found to be more effective than O.D. dosage 11 . The diagnosis of LPR is often difficult 10 .…”

Section: Introductionmentioning

confidence: 99%

Analyzing various non-surgical treatment modalities for laryngopharyngeal reflux

Owais

Rahil

Anees

et al. 2012

Bangladesh J of Otorhinolaryngology

View full text Add to dashboard Cite

show abstract

“…Recommendations of treatment with PPIs in suspected LPR are based on the results of a number of open label studies (Kamel et al 1994;Hanson 1995;Jaspersen et al 1996;Habermann et al 1999;Shaw and Searl 1997;Wo et al 1997;Ulualp et al 2001;Delgaudio and Waring 2003;Park et al 2005;Siupsinskiene et al 2007). These are all uncontrolled studies investigating the effect of a PPI at varying doses on symptoms and laryngeal fi ndings with treatment lasting from 6 to 24 weeks.…”

Section: Results From Open-label Trialsmentioning

confidence: 99%

Management of laryngopharyngeal reflux with proton pump inhibitors

Reimer

Bytzer²

2008

TCRM

View full text Add to dashboard Cite

Abstract:There is a lack of consistent guidelines and consensus for the diagnosis of laryngopharyngeal refl ux (LPR). A therapeutic trial with a proton pump inhibitor (PPI) has been suggested to identify patients with LPR. This review focuses on the current diffi culties in diagnosing the disease and examines the evidence for the effectiveness of PPI therapy in suspected refl ux-related laryngeal symptoms. Additionally, mode of action, safety, and tolerability of PPIs are described. A total of 7 placebo-controlled trials were identifi ed and included in the review. All studies evaluated the effect of a PPI on symptoms and objective laryngoscopic fi ndings in suspected LPR. Data from these trials show that PPI therapy is no more effective than placebo in producing symptom relief in patients suspected of LPR. Symptoms, laryngoscopic fi ndings, or abnormal fi ndings on pH monitoring will not predict response to PPI therapy. High placebo response levels suggest a much more complex and multifactorial pathophysiology of LPR than simple acid refl ux. Further studies are needed to characterize subgroups of patients with refl ux-associated laryngeal symptoms that might benefi t from treatment with PPI. Future studies should use validated patient reported outcome measures with endpoints that represent a predefi ned clinically meaningful change in symptom scores.

show abstract

“…Batuk dan tersedak diinduksi oleh iritasi refluks pada saraf sensori laring yang sangat sensitif yang disebabkan akumulasi sekret dan zat asam. 12 Pada penelitian ini ditemukan keluhan suara Tantri Kurniawati: Perbandingan Efektivitas antara Omeprazol dan Lansoprazol terhadap Perbaikan Kualitas Hidup serak pada 5/10 omeprazol dan 3/10 lansoprazol, selain disebabkan oleh refluks, karena subjek penelitian ini adalah penderita rinosinusitis kronik, maka ada kemungkinan keluhan yang ditimbulkan juga diakibatkan postnasal drip akibat rinosinusitis kronik, yang juga dapat menyebabkan suara serak. 17 Keluhan RLF yang dirasakan oleh penderita tersebut disebabkan tidak terdapat mekanisme pertahanan zat asam di daerah saluran napas atas sehingga zat asam dalam jumlah sedikit pun dapat menyebabkan gejala RLF yang signifikan.…”

Section: Pembahasanunclassified

Perbandingan Efektivitas antara Omeprazol dan Lansoprazol terhadap Perbaikan Kualitas Hidup Penderita Rinosinusitis Kronik Akibat Refluks Laringofaring

Kurniawati¹,

Madiadipoera²,

Sarbini³

et al. 2012

mkb

View full text Add to dashboard Cite

AbstrakRefluks laringofaring (RLF) adalah refluks cairan lambung melalui esofagus ke daerah laringofaring. Prevalensi RLF 15-20%, dan menjadi salah satu penyebab rinosinusitis kronik. Insidensi RLF pada penderita rinosinusitis kronik sebesar 37-72%. Prevalensi rinosinusitis kronik 16,3% pada dewasa dan berefek terhadap kualitas hidup. Omeprazol dan lansoprazol adalah proton pump inhibitor (PPI), digunakan sebagai terapi RLF, juga digunakan pada rinosinusitis kronik akibat RLF. Effectiveness Comparison between Omeprazole and Lansoprazole on the Improvement of Quality of Life in Patients with Chronic RhinosinusitisCaused by Laryngopharyngeal Reflux AbstractLaryngopharyngeal reflux (LPR) is the reflux of gastric acid through the esophagus that reaches laringopharyngeal area. The prevalence of LPR in the range 15-20%, and caused chronic rhinosinusitis (CRS). The incidence of LPR in patients with CRS has ranged between 37-72%. The prevalence of CRS 16,3% in adults and affecting quality of life. Omeprazole and lansoprazole are proton pump inhibitors (PPIs) for LPR's therapy and also a therapy for CRS with LPR as the etiology. This research method was randomized clinical trial with open trial observation, conducted in June to December 2009. Twenty subjects with consecutive sampling method, divided into two groups (with simple randomization), the first group received omeprazole and the other lansoprazole. The subjects conducted complete physical otolaryngology examination, sino-nasal outcome test 20, reflux symptom index and reflux finding score with fiber optic rhinolaryngoscopy. These data was obtained before therapy, after 2 weeks and two months therapy, analyzed with Wilcoxon's and Mann-Whitney's test. There was no effectivity difference between omperazole and lansoprazole in reducing the level of severity of LPR (p>0.05), but quality of life improvement was better in lansoprazole than omeprazole group (p<0.05). In conclusion, lansoprazole is more effective than omeprazole in improvement of quality of life in patients with chronic rhinosinusitis caused by LPR. [MKB. 2012;44(3):138-46].

show abstract

Laryngopharyngeal Reflux: Prospective Cohort Study Evaluating Optimal Dose of Proton-Pump Inhibitor Therapy and Pretherapy Predictors of Response

Abstract: BID PPI appears to be more effective than QD PPI in achieving clinical symptom response in suspected LPR. More response was achieved at 4 months compared with 2 months. Therefore, aggressive acid suppression with BID PPI for at least 4 months is warranted for treatment of LPR.

Cited by 230 publications

References 13 publications

Analyzing various non-surgical treatment modalities for laryngopharyngeal reflux

Analyzing various non-surgical treatment modalities for laryngopharyngeal reflux

Management of laryngopharyngeal reflux with proton pump inhibitors

Perbandingan Efektivitas antara Omeprazol dan Lansoprazol terhadap Perbaikan Kualitas Hidup Penderita Rinosinusitis Kronik Akibat Refluks Laringofaring

Contact Info

Product

Resources

About